The Belgian Competition Authority (BCA) has opened formal proceedings against IQVIA, a global company involved in pharmaceutical data collection and processing, for suspected abuse of dominant position.

This investigation follows a complaint and a preliminary inquiry that indicated serious violations of competition rules. The BCA's focus is on IQVIA's contractual practices within a highly concentrated pharmaceutical sector in Belgium.

According to the BCA, the preliminary analysis of the evidence provided by the complainant and information requests to various industry players revealed significant indications of potential infringements of Article 102 TFEU and Article IV.2 of the Code of Economic Law (CEL).

The BCA has prioritized the pharmaceutical and healthcare sectors in its enforcement efforts, and the opening of this investigation does not imply any predetermined outcome. IQVIA will be fully involved in the proceedings as the investigation progresses.

Individuals can report suspected anti-competitive practices through the BCA’s secure reporting line available on their website.